As a key regulator of tumor angiogenesis 2,3, VEGF is enriched in cancer patient plasma and serum samples 4–7, and the approach of sequestering VEGF to attenuate signaling and prevent abnormal vascularization 8,9 in the form of antibodies, small molecule tyrosine kinase inhibitors, and peptides 10–12 has been applied toward treating metastatic breast cancer, metastatic colorectal cancer, and glioblastoma multiforme—the most common and most aggressive form of brain cancer 8,13. This evidence concerns the gene VEGFA and glioblastoma.